Societal CDMO Reports Inducement Grants for New Staff
SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract […]
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering […]
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its […]
A-Mark Precious Metals Announces Quarterly Cash Dividend
EL SEGUNDO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark), a leading fully integrated […]
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics […]
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from […]
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, […]
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Cash runway anticipated to be extended from Q2 2025 to Q4 2025 Data from multiple Phase 1 and 2 clinical […]
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted […]
First Hawaiian to Report Fourth Quarter 2023 Financial Results on January 26, 2024
HONOLULU, Jan. 05, 2024 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its […]
